• 1
    National Institutes of Health, National Heart, Lung and Blood Institute. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults — The Evidence Report. Obes Res 1998; 6(Suppl. 2): 1S209S.
  • 2
    Anonymous. Overweight, obesity, and health risk. National Task Force on the Prevention and Treatment of Obesity. Arch Intern Med 2000; 160: 898904.
  • 3
    Klein S, Wadden TA, Sugerman HJ. AGA technical review on obesity. Gastroenterology 2002; 123: 882932.
  • 4
    Maclure KM, Hayes KC, Colditz GA, Stampfer MJ, Speizer FE, Willett WC. Weight, diet and the risk of symptomatic gallstones in middle-aged women. N Engl J Med 1989; 321: 5639.
  • 5
    Stampfer MJ, Maclure KM, Colditz GA, et al. Risk of symptomatic gallstones in women with severe obesity. Am J Clin Nutr 1992; 55: 6528.
  • 6
    Weatherall R, Shaper AG. Overweight and obesity in middle-aged British men. Eur J Clin Nutr 1998; 42: 22131.
  • 7
    Kato I, Nomura A, Stemmermann GN, Chyou PH. Prospective study of clinical gallbladder disease and its association with obesity, physical activity, and other factors. Dig Dis Sci 1992; 37: 78490.
  • 8
    Kodama I, Kono S, Honjo S, et al. Gallstone disease risk in relation to body mass index and waist-to-hip ratio in Japanese men. Int J Obes Relat Metab Disord 1999; 23: 2116.
  • 9
    Heaton KW, Braddon FEM, Emmett PM, et al. Why do men get gallstones? Role of abdominal fat and hyperinsulinaemia. Eur J Gastroenterol Hepatol 1991; 3: 74551.
  • 10
    Broomfield PH, Chopra R, Shunbaum RC, et al. Effect of ursodeoxycholic acid and aspirin on the formation of lithogenic bile and gallstones during loss of weight. N Engl J Med 1988; 319: 156772.
  • 11
    Liddle RA, Goldstein RB, Saxton J. Gallstone formation during weight-reduction dieting. Arch Intern Med 1989; 149: 17503.
  • 12
    Yang H, Peterson GM, Roth M-P, Schoenfield LJ, Marks JW. Risk factors for gallstone formation during rapid loss of weight. Dig Dis Sci 1992; 37: 9128.
  • 13
    Kamrath RO, Plummer LJ, Sadur CN, et al. Cholelithiasis in patients treated with a very-low-calorie diet. Am J Clin Nutr 1992; 56: 255S257S.
  • 14
    Wattchow DA, Hall JC, Whiting MJ, Bradley B, Iannos J, Watts JM. Prevalence and treatment of gallstones after gastric bypass surgery for obesity. Br Med J 1983; 286: 763.
  • 15
    Shiffman ML, Sugerman HJ, Kellum JM, Brewer WH, Moore EW. Gallstone formation after rapid weight loss: a prospective study in patients undergoing gastric bypass surgery for treatment of morbid obesity. Am J Gastroenterol 1991; 86: 10005.
  • 16
    Shiffman ML, Sugerman HJ, Kellum JM, Moore EW. Changes in gallbladder bile composition following gallstone formation and weight reduction. Gastroenterology 1992; 103: 21421.
  • 17
    Shiffman ML, Sugerman HJ, Kellum JH, Brewer WH, Moore EW. Gallstones in patients with morbid obesity. Relationship to body weight, weight loss and gallbladder bile cholesterol solubility. Int J Obes Relat Metab Disord 1993; 17: 1538.
  • 18
    Everhart JE. Contributions of obesity and weight loss to gallstone disease. Ann Intern Med 1993; 119: 102935.
  • 19
    Hoy MK, Heshka S, Allison DB, et al. Reduced risk of liver-function-test abnormalities and new gallstone formation with weight loss on 3350-kJ (800-kcal) formula diets. Am J Clin Nutr 1994; 60: 24954.
  • 20
    Weinsier RL, Wilson LJ, Lee J. Medically safe rate of weight loss for the treatment of obesity: a guideline based on risk of gallstone formation. Am J Med 1995; 98: 1157.
  • 21
    Festi D, Colecchia A, Orsini M, et al. Gallbladder motility and gallstone formation in obese patients following very low calorie diets. Use it (fat) to lose it (well). Int J Obes Relat Metab Disord 1998; 22: 592600.
  • 22
    Erlinger S. Gallstones in obesity and weight loss. Eur J Gastroenterol Hepatol 2000; 12: 134752.
  • 23
    Hay DW, Carey MC. Pathophysiology and pathogenesis of cholesterol gallstone formation. Semin Liver Dis 1990; 10: 15970.
  • 24
    Johnston DE, Kaplan MM. Pathogenesis and treatment of gallstones. N Engl J Med 1993; 328: 41221.
  • 25
    O'Donnell LJ, Fairclough PD. Gall stones and gall bladder motility. Gut 1993; 34: 4403.
  • 26
    Capron JP, Delamarre J, Herve MA, Dupas JL, Poulain P, Descombes P. Meal frequency and duration of overnight fast: a role in gall stone formation? Br Med J 1981; 283: 1435.
  • 27
    Attili AF, Scafato E, Marchioli R, Marfisi RM, Festi D and the MICOL group. Diet and gallstones in Italy: the cross-sectional MICOL results. Hepatology 1998; 27: 14928.
  • 28
    Syngal S, Coakley EH, Willett WC, Byers T, Williamson DF, Colditz GA. Long-term weight patterns and risk for cholecystectomy in women. Ann Intern Med 1999; 130: 4716.
  • 29
    Erpecum KJv, Berge-Henegouwen GPv. Gallstones: an intestinal disease? Gut 1999; 44: 4358.
  • 30
    Andersen T. Liver and gallbladder disease before and after very-low-calorie diets. Am J Clin Nutr 1992; 56(Suppl.): 235S239S.
  • 31
    Jebbink MCW. Regulation of secretion and actions of cholecystokinin in man. Studies with the cholecystokinin-receptor antagonist loxiglumide. MD Thesis. Leiden: University of Leiden, 1992.
  • 32
    Douglas BR, Jebbink MCW, Tjon A, Tham RTO, Jansen JBMJ, Lamers CBHW. The effect of loxiglumide (CR 1505) in basal and bombesin stimulated gallbladder volume in man. Eur J Pharmacol 1989; 166: 30710.
  • 33
    Malesci A, DeFazio C, Festorazzi S, et al. Effect of loxiglumide on gallbladder contractile response to caerulein and foods in man. Gastroenterology 1990; 98: 130710.
  • 34
    Hopman WP, Jansen JBMJ, Lamers CBHW. Comparative study of the effects of equal amounts of fat, protein and starch on plasma cholecystokinin in man. Scand J Gastroenterol 1985; 20: 8437.
  • 35
    Hopman WP, Jansen JB, Rosenbusch G, Lamers CB. Effect of equimolar amounts of long-chain triglycerides and medium-chain triglycerides on plasma cholecystokinin and gallbladder contraction. Am J Clin Nutr 1984; 39: 3569.
  • 36
    Isaacs PET, Ladas S, Forgacs IC, et al. Comparison of effects of ingested medium- and long-chain triglycerides on gallbladder volume and release of cholecystokinin and other gut hormones. Dig Dis Sci 1987; 32: 4816.
  • 37
    Ledeboer M. Intraluminal nutrients and gastrointestinal motility with emphasis on the effects of dietary fat. MD Thesis. Leiden: University of Leiden, 1995.
  • 38
    McLaughin J, Luca MG, Jones MN, D'Amato M, Dockray GJ, Thompson DG. Fatty acid chain length determines cholecystokinin secretion and effect on human gastric motility. Gastroenterology 1999; 116: 4653.
  • 39
    Jansen JBMJ, Jebbink MCW, Mulders HJA, Lamers CBHW. Effect of pancreatic enzyme supplementation on postprandial plasma cholecystokinin secretion in patients with pancreatic insufficiency. Scand J Gastroenterol 1989; 20: 8437.
  • 40
    Masclee AA, Jansen JBMJ, Corstens FH, Lamers CBHW. Reversible gall bladder dysfunction in severe pancreatic insufficiency. Gut 1989; 30: 86672.
  • 41
    De Boer SY, Masclee AA, Jebbink MCW, Schipper J, Jansen JBMJ, Lamers CBHW. Effect of intravenous fat on cholecystokinin secretion and gallbladder motility in man. J Parenter Enteral Nutr 1992; 16: 169.
  • 42
    Hopman WP, Rosenbusch G, Hectors MP, Jansen JB. Effect of predigested fat on intestinal stimulation of plasma cholecystokinin and gall bladder motility in coeliac disease. Gut 1995; 36: 1721.
  • 43
    Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the dose–response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994; 56: 825.
  • 44
    Hussain Y, Guzelhan C, Odink J, Van Der Beek EJ, Hartmann D. Comparison of the inhibition of dietary fat absorption by full versus divided doses of orlistat. J Clin Pharmacol 1994; 34: 11215.
  • 45
    Van Gaal LF, Broom JI, Enzi G, Toplak H, The Orlistat Dose-Ranging Study Group. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Eur J Clin Pharmacol 1998; 54: 12532.
  • 46
    World Health Organization. Energy and protein requirements. Report of a joint FAO/WHO/UNU expert consultation. Technical Reports Series 729. Geneva: World Health Organization, 1985.
  • 47
    Everson GT, Braverman DZ, Johnson ML, Kern F Jr. A critical evaluation of real-time ultrasonography for the study of gallbladder volume and contraction. Gastroenterology 1980; 79: 406.
  • 48
    Dodds WJ, Groh WJ, Darweesh RMA, Lawson TL, Kishk SMA, Kern MK. Sonographic measurements of gallbladder. Am J Roentgenol 1985; 145: 100911.
  • 49
    Wedman B, Schmidt G, Wegener M, Coenen C, Ricken D, Droge C. Sonographic evaluation of gallbladder kinetics: in vitro and in vivo comparison of different methods to assess gallbladder emptying. J Clin Ultrasound 1991; 19: 3419.
  • 50
    Jansen JBMJ, Lamers CB. Radioimmunoassay of cholecystokinin in human tissue and plasma. Clin Chim Acta 1983; 131: 30516.
  • 51
    Froehlich F, Gonvers JJ, Fried M. Role of nutrient fat and cholecystokinin in regulation of gallbladder emptying in man. Dig Dis Sci 1995; 40: 52933.
  • 52
    Gebhard RL, Prigge WF, Ansel HJ, et al. The role of gallbladder emptying in gallstone formation during diet-induced rapid weight loss. Hepatology 1996; 24: 5448.
  • 53
    Froehlich F, Hartmann D, Guezelhan C, Gonvers JJ, Jansen JB, Fried M. Influence of orlistat on the regulation of gallbladder contraction in man: a randomized double-blind placebo-controlled crossover study. Dig Dis Sci 1996; 41: 24048.
  • 54
    Borovicka J, Schwizer W, Guttmann G, et al. Role of lipase in the regulation of postprandial gastric acid secretion and emptying of fat in humans: a study with orlistat, a highly specific lipase inhibitor. Gut 2000; 46: 77481.
  • 55
    Meyer JH, Elashoff JD, Domeck M, et al. Control of canine gastric emptying of fat by lipolytic products. Am J Physiol 1994; 266: G101735.
  • 56
    Schwizer W, Asal K, Kreiss C, et al. Role of lipase in the regulation of upper gastrointestinal function in humans. Am J Physiol 1997; 273: G61220.
  • 57
    Hildebrand P, Petrig C, Burckhardt B, et al. Hydrolysis of dietary fat by pancreatic lipase stimulates cholecystokinin release. Gastroenterology 1998; 114: 1239.
  • 58
    Trouillot TE, Pace DG, McKinley C, et al. Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss. Am J Gastroenterol 2001; 96: 188894.
    Direct Link:
  • 59
    James WTP, Avenell A, Broom J, Whitehead J. A one-year trial to assess the value of orlistat in the management of obesity. Int J Obes Relat Metab Disord 1999; 21(Suppl. 3): S2430.
  • 60
    Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998; 21: 128893.
  • 61
    Finer N, James WPT, Kopelman PG, Lean MEJ, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000; 24: 30613.
  • 62
    Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res 2000; 8: 4961.
  • 63
    Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabet Obes Metab 2002; 4: 41523.